# Moderna financial and research developments

> Developing situation record from CLSTR: https://clstr.news/situations/moderna-financial-and-research-developments
> Updated: 2026-11-06T11:18:51.000Z. Sources: 7. Developments: 2.

Moderna experienced significant market and operational shifts in late 2026. In October, company shares reached a four year high following news of a planned public-private partnership with the National Institutes of Health and other institutions to accelerate cancer vaccine development. This initiative, modeled after COVID-19 pandemic collaborations, was expected to launch in December.

By November, Moderna reported third quarter 2026 financial results showing a return to profitability with a net profit of $162 million, compared to a loss in the same period the previous year. Revenue rose 29 percent to $1.31 billion, driven largely by international demand for COVID-19 vaccines. During this period, the company also noted progress in its oncology and infectious disease pipelines, including plans to present data on multiple myeloma therapy and a recommendation for its Ebola vaccine candidate to enter Phase 2/3 trials.

## Claims

- Moderna reported Q3 2026 revenue of $1.31 billion. (reported by 2 sources)
- Revenue increased by 29% year-on-year. (reported by 2 sources)
- GAAP diluted earnings per share was $0.38. (reported by 2 sources)
- Moderna recorded a net profit of $162 million in Q3 2026. (reported by 1 source)
- Moderna raised annual revenue projections to a range of 15% to 25% for the end of 2026. (reported by 1 source)
- The WHO advisory group recommended Moderna's Ebola vaccine candidate, mRNA-1469, be included in a Phase 2/3 trial in the Democratic Republic of the Congo. (reported by 1 source)
- Moderna's stock rose 13% in a single session on November 4. (reported by 1 source)
- Intismeran combined with Merck's Keytruda showed a 42% lower relative risk of melanoma recurrence or death in published findings. (reported by 1 source)

## Timeline

### 2026-11-06: Moderna reports $1.31 billion in Q3 2026 revenue and returns to profitability

Moderna reported Q3 2026 revenue of $1.31 billion, a 29% year-on-year increase, returning to a net profit of $162 million.

7 sources. https://clstr.news/cluster/moderna-reports-131-billion-in-q3-2026-revenue-and-returns-to-profitability

### 2026-10-08: Moderna shares hit four-year high on cancer vaccine news

Moderna shares hit a four-year high following news of a planned NIH-backed public-private partnership to accelerate cancer vaccine development and the company's return to the Nasdaq-100 index.

9 sources. https://clstr.news/cluster/nvidia-stock-rises-amid-tsmc-record-revenue-and-chip-sector-optimism

---
Cite as: Moderna financial and research developments. CLSTR, https://clstr.news/situations/moderna-financial-and-research-developments